On December 5, 2019 OncoSec Medical Incorporated ("OncoSec") (Nasdaq: ONCS), a company developing late-stage intratumoral cancer immunotherapies, reported it will present interim efficacy, immunological and safety data from its ongoing KEYNOTE-890 study of TAVO in combination with KEYTRUDA in patients with late-stage, heavily pretreated, chemo-refractory metastatic triple negative breast cancer (mTNBC) at the upcoming San Antonio Breast Cancer Symposium (SABCS) Annual Meeting being held December 10-14, 2019 (Press release, OncoSec Medical, DEC 5, 2019, View Source [SID1234551971]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster, titled "Phase 2, open-label study of intratumoral tavokinogene telseplasmid (tavo) plus electroporation in combination with intravenous pembrolizumab therapy in patients with inoperable locally advanced or metastatic triple negative breast cancer (mTNBC) (KEYNOTE- 890/OMS-I141)," will be presented by lead author Melinda L. Telli, MD on Thursday, December 12th from 5:00 p.m. – 7:00 p.m. CST.

The SABCS abstracts are listed on the conference website under Abstracts at View Source!/7946 .

On December 5, 2019 Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, reported that Mr. Jed Latkin, Chief Executive Officer, will present at the 12th Annual LD Micro Main Event investor conference (Press release, Navidea Biopharmaceuticals, DEC 5, 2019, View Source [SID1234551967]). The conference will be held at the Luxe Bel Air Hotel in Los Angeles, CA on December 10-12, 2019. Mr. Latkin will present on Wednesday, December 11 at 10:20 a.m. PT (1:20 p.m. ET) in Track 4, which will be webcast.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of Navidea’s presentation are below. For those who wish to listen to the live webcast, please use the following link: View Source." target="_blank" title="View Source." rel="nofollow">View Source The webcast will be archived on Navidea’s investor relations website, View Source for 90 days following the live presentation.

Event:

12th Annual LD Micro Main Event

Date:

Wednesday, December 11, 2019

Time:

10:20 a.m. PT (1:20 p.m. ET)

Location:

Luxe Sunset Boulevard Hotel, Los Angeles, CA – Track 4

Webcast:

View Source

The 12th Annual LD Micro Main Event will feature 275 emerging growth companies and is expected to attract 1,500 attendees. To schedule a one-on-one meeting with Mr. Latkin, please contact Adam Holdsworth at [email protected].

On December 5, 2019 Incyte Corporation (Nasdaq:INCY) reported that it will present at the J. P. Morgan 38th Annual Healthcare Conference on Monday, January 13, 2020 at 8:30 am (PST) in San Francisco (Press release, Incyte, DEC 5, 2019, View Source [SID1234551966]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast live and can be accessed at www.incyte.com under For Investors, Events and Presentations and will be available for replay for 30 days. Investors interested in listening to the live webcast should log on before the start time in order to download any software required.

On December 5, 2019 Genmab A/S (Nasdaq: GMAB) reported that at a board meeting the board decided to grant 83,658 restricted stock units to members of the board of directors, two members of management and employees of the company as well as the company’s subsidiaries and 195,011 warrants to employees of the company and the company’s subsidiaries (Press release, Genmab, DEC 5, 2019, View Source [SID1234551965]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. The vesting of the restricted stock units granted to the two members of management will be subject to forward looking performance criteria. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK 1,615.

The restricted stock units will vest on the first banking day of the month following a period of three years from the date of grant. Furthermore, the restricted stock units are subject to vesting conditions set out in the restricted stock unit program adopted by the board of directors in accordance with the general guidelines for incentive-based remuneration adopted by the shareholders at the annual general meeting. Information concerning Genmab’s restricted stock unit program can be found on www.genmab.com under Investors > Stock information > Restricted stock units.

The exercise price for each warrant is DKK 1,615. Each warrant is awarded cost-free and entitles the owner to subscribe one share of nominally DKK 1 subject to payment of the exercise price. By application of the Black-Scholes formula, the fair value of each warrant can be calculated as DKK 458.61

The warrants vest three years after the grant date, and all warrants expire at the seventh anniversary of the grant date. The new warrants have been granted on the terms and conditions set out in the warrant program adopted by the board of directors on March 28, 2017. Information concerning Genmab’s warrant schemes can be found on www.genmab.com under Investors > Stock information > Warrants.

On December 5, 2019 Eli Lilly and Company (NYSE: LLY) reported new leadership and strategic direction in oncology R&D, combining the Lilly Research Laboratories (LRL) oncology organization and Loxo Oncology, which was acquired by Lilly in early 2019 (Press release, Eli Lilly, DEC 5, 2019, View Source [SID1234551964]). The new organization, named Loxo Oncology at Lilly, will be led jointly by Josh Bilenker, M.D., Jacob Van Naarden, and Nisha Nanda, Ph.D., and will report into Daniel Skovronsky, M.D., Ph.D., Lilly’s chief scientific officer and president of Lilly Research Laboratories. Lilly today also announced that David Hyman, M.D. will join the leadership team as chief medical officer of the new organization, beginning in January 2020. Dr. Hyman currently serves as chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The Loxo Oncology acquisition has brought talented people and new approaches to Lilly, and we are excited by what we can achieve by incorporating their discovery and development philosophy at a much larger scale. With the addition of Dr. Hyman, we are further strengthening our leadership team in oncology," said Skovronsky. "We will focus our efforts on biology insights with the greatest near-term potential for patients. We intend to curate a balanced pipeline of medicines—whether internally or externally discovered—to help even more people with cancer around the world and position Lilly as a premier oncology company."

The new combined organization will be responsible for discovery research across therapeutic modalities, clinical development and regulatory affairs for oncology. As new medicines approach US regulatory approval, program responsibility will transition to Lilly’s Oncology Business Unit, led by Anne White, for continued clinical development, commercialization and medical affairs support.

The new Loxo Oncology at Lilly organization will have an expanded global presence, with team members in Boulder, Colorado; Indianapolis, Indiana; New York City, New York; South San Francisco, California; Stamford, Connecticut; and Madrid, Spain.

Areas of focus for Loxo Oncology at Lilly currently include registration of selpercatinib (a selective RET inhibitor), and clinical development of LOXO-305 (a selective, non-covalent BTK inhibitor), LY3499446 (a selective, covalent KRAS G12C inhibitor), and LY3484356 (a selective estrogen receptor degrader). The new organization will also pursue acquisition and in-licensing opportunities. In connection with these changes, development of several early clinical-stage programs will be wound down and terminated. Further details will be provided during Lilly’s Q4 2019 earnings call, scheduled for January 30, 2020.